Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase ( LSD1 )/ MAO-B inhibitor In Vitro Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer's disease. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:LSD1/MAO-B
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Vafidemstat
CAS number:1357362-02-7 molecular formula:C19H20N4O2
overview
compound introduction
Specs
| Chinese alias | 伐地那非 | ||
| English alias | (1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine | MS-25100 | BCP29383 | ORY 2001; ORY-2001; ORY2001 | AKOS040742807 | UNII-LZ82JLT4UP | 1357362-02-7 | 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino | ||
| CAS number | 1357362-02-7 | molecular formula | C19H20N4O2 |
| molecular weight | 336.39 g/mol | Exact mass | ≥98% |
| PSA | 86.200 Ų | logp | 2.200 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS





